Literature DB >> 26452667

Baseline MELD-XI score and outcome from veno-arterial extracorporeal membrane oxygenation support for acute decompensated heart failure.

Hoong Sern Lim1.   

Abstract

BACKGROUND: Acute decompensated heart failure is the most common acute heart failure phenotype. Veno-arterial extracorporeal membrane oxygenation (VA-ECMO) can provide bridging support for patients with acute decompensated heart failure to transplantation. We studied the association between baseline (<6 months), pre-ECMO (<24 h) parameters and outcome of VA-ECMO support in patients with severe acute decompensated heart failure.
METHODS: We included 26 consecutive patients with acute decompensated heart failure (acute myocarditis, myocardial infarction or post-cardiotomy shock were excluded) who were bridged with peripheral VA-ECMO to transplantation. Data within six months (baseline) and immediately pre-ECMO were collected. Model for end-stage liver disease (MELD) with sodium (MELD-Na) and without international normalized ratio (MELD-XI) scores were calculated. Outcome was defined as death at 30 days following VA-ECMO support.
RESULTS: Thirteen of the 26 patients died within 30 days of VA-ECMO support. Univariate associations with 30-day mortality were baseline MELD-XI, baseline sodium, creatinine, bilirubin, pre-ECMO alanine aminotransferase and lactate. However, only baseline MELD-XI score (hazard ratio 2.678 (95% CI 1.085-6.607), p=0.033) was associated 30-day survival on logistic regression analysis. Survivors demonstrated greater reduction in inotropic and vasoactive drug support and improvement in alanine aminotransferase and lactate levels. Using a threshold based on the median MELD-XI of 14.1, 30-day survival in patients with a baseline MELD-XI ⩽ 14.1 was 69% compared with 31% in patients with baseline MELD-XI > 14.1 ( p=0.046).
CONCLUSION: Baseline MELD-XI score, but not pre-ECMO parameters, is independently associated with outcomes from VA-ECMO support in patients with acute decompensated heart failure.

Entities:  

Keywords:  Heart failure; extracorporeal membrane oxygenation

Mesh:

Year:  2016        PMID: 26452667     DOI: 10.1177/2048872615610865

Source DB:  PubMed          Journal:  Eur Heart J Acute Cardiovasc Care        ISSN: 2048-8726


  6 in total

1.  Serum Total Bilirubin With Hospital Survival in Adults During Extracorporeal Membrane Oxygenation.

Authors:  Rui Huang; Min Shao; Cheng Zhang; Ming Fang; Mengmeng Jin; Xuan Han; Nian Liu
Journal:  Front Med (Lausanne)       Date:  2022-06-24

Review 2.  Mechanical Circulatory Support for Decompensated Heart Failure.

Authors:  Tarique Al Musa; Colin Dominic Chue; Hoong Sern Lim
Journal:  Curr Heart Fail Rep       Date:  2017-10

3.  Model for End-stage Liver Disease excluding INR (MELD-XI) score in critically ill patients: Easily available and of prognostic relevance.

Authors:  Bernhard Wernly; Michael Lichtenauer; Marcus Franz; Bjoern Kabisch; Johanna Muessig; Maryna Masyuk; Uta C Hoppe; Malte Kelm; Christian Jung
Journal:  PLoS One       Date:  2017-02-02       Impact factor: 3.240

4.  Impact of dynamic changes of elevated bilirubin on survival in patients on veno-arterial extracorporeal life support for acute circulatory failure.

Authors:  Miriam Freundt; Dirk Lunz; Alois Philipp; Bernd Panholzer; Matthias Lubnow; Christine Friedrich; Leopold Rupprecht; Stephan Hirt; Assad Haneya
Journal:  PLoS One       Date:  2017-10-19       Impact factor: 3.240

5.  Predictors associated with mortality of extracorporeal life support therapy for acute heart failure: single-center experience with 679 patients.

Authors:  Sebastian D Sahli; Alexander Kaserer; Donat R Spahn; Markus J Wilhelm; Julia Braun; Maximilian Halbe; Yuliya Dahlem; Muriel A Spahn; Julian Rössler; Bernard Krüger; Francesco Maisano
Journal:  J Thorac Dis       Date:  2022-06       Impact factor: 3.005

6.  MELD score as a predictor of mortality, length of hospital stay, and disease burden: A single-center retrospective study in 39,323 inpatients.

Authors:  Jan A Roth; Carl Chrobak; Sabine Schädelin; Balthasar L Hug
Journal:  Medicine (Baltimore)       Date:  2017-06       Impact factor: 1.817

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.